China Biotech Weekly #8: WuXi AppTec Earnings — Revenue Up, BIOSECURE Risk Priced In

This Week's Top Takeaway

WuXi AppTec's (药明康德) Q4 2025 earnings reveal a paradox: US client revenue continues to grow even as BIOSECURE compliance risk intensifies. Revenue from US clients increased approximately 8% year-over-year in Q4 2025, suggesting that most clients are maintaining contracts while simultaneously building contingency plans. The brief 1260H listing one week ago — and its unexplained withdrawal — has not yet triggered a measurable client exodus. But the compliance clock is ticking.

BIOSECURE Watch: Post-1260H Analysis

Status: 🟡 Elevated Uncertainty

One week after the Pentagon's brief publication and withdrawal of a 1260H list update that included WuXi AppTec:

No new 1260H list published. The withdrawn list remains the most recent action. DoD has not commented on the withdrawal rationale.
WuXi share price: Recovered approximately 60% of the ~8% drop that occurred during the brief listing. Market pricing implies significant but not certain BIOSECURE risk.
Congressional response: Members of the House Select Committee on China publicly expressed frustration with the withdrawal, calling it "inconsistent with congressional intent." This suggests continued political pressure for WuXi's inclusion on the next 1260H update.
SEC disclosures: Now approximately 10 public companies have added BIOSECURE risk factors.

CDE Filing Watch

WuXi Biologics (药明生物) filed manufacturing process documentation with CDE for its Wuxi and Shanghai facilities. These filings — routine manufacturing supplements — confirm that WuXi continues to invest in Chinese production capacity despite BIOSECURE uncertainty.

Akeso (康方生物) received CDE priority review designation for ivonescimab in a new solid tumor indication. Each additional CDE-approved indication strengthens the commercial case for Summit's FDA submission and expands the potential market for the ex-China license.

Takeaways for BD Teams

"Hedge, don't exit" is the industry's WuXi strategy — but it has a shelf life. Client retention above 95% today doesn't mean retention at 95% in 12 months. If the BCC list drops in December 2026 with WuXi included, the companies that only hedged (without completing tech transfer) will face 18-24 months of disruption.

The WuXi XDC IPO is a compliance bet. If OMB interprets Category C narrowly (wholly-owned subsidiaries only), the IPO creates structural separation. If OMB interprets it broadly (any entity under common control), the IPO may not provide protection. Your compliance plan should cover both scenarios.

Congressional frustration with the 1260H withdrawal is a signal. The withdrawal was administrative, not substantive. Expect continued and potentially escalating pressure for WuXi's 1260H inclusion. Do not treat the withdrawal as a safety signal.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan